By immunoblotting of patient‐derived cells, EphA2 (total and phosphorylated), GPRC5A, and RSK showed variable expression in the cancer cells, whereas GPRC5A was undetectable and RSK low in patient‐derived CAFs (Fig 8B). This evidence concerns the gene GPRC5A and cancer.